Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New psoriasis pill shows promise in Mid-Stage trial

NCT ID NCT05223868

Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called JNJ-77242113 in 255 adults with moderate-to-severe plaque psoriasis. The goal was to see if different doses could clear at least 75% of skin symptoms after 16 weeks compared to a placebo. Participants had psoriasis for at least 6 months and were candidates for light therapy or systemic treatment. The results help determine the best dose for future studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

255 people

The number who actually took part.

Started

Feb 2022

Finished

Dec 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant has a diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), for at least 6 months prior to the first administration of study intervention * Participant be a candidate for phototherapy or systemic treatment for plaque psoriasis * Participant has a total body surface area (BSA) greater than or equal to (\>=)10 percent (%) at screening and baseline * Participant has a total Psoriasis area and severity index (PASI) \>=12 at screening and baseline * Participant has a total Investigator global assessment (IGA) \>=3 at screening and baseline Exclusion Criteria: * Participant has a nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular) * Participant has current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium) * Participant have previously received any other therapeutic agent directly targeted to interleukin 23 receptor (IL-23R) (including but not limited to guselkumab, tildrakizumab, or risankizumab) * Participant has received any therapeutic agent directly targeted to interleukin 17 receptor (IL-17) or interleukin 12/23 receptor (IL-12/23) (including but not limited to secukinumab, ixekizumab, brodalumab, or ustekinumab) or has received anti-tumor necrosis factor \[TNF\]-alpha biologic therapy (including, but not limited to adalimumab) within 12 weeks or 5 half-lives, whichever is longer, of the first administration of study intervention * Participant has received agents that deplete B cells (including, but not limited to, rituximab, or alemtuzumab) within 26 weeks of the first administration of study intervention

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Plaque psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Plaque psoriasis

Contacts and locations

Locations

  • Alliance Clinical Trials

    Waterloo, Ontario, N2J 1C4, Canada

  • Arlington Dermatology

    Rolling Meadows, Illinois, 60008, United States

  • Atlanta Dermatology, Vein & Research Center

    Alpharetta, Georgia, 30022, United States

  • Austin Institute for Clinical Research

    Pflugerville, Texas, 78660, United States

  • Castle Hill Hospital

    Cottingham, HU16 5JQ, United Kingdom

  • Center for Clinical Studies

    Houston, Texas, 77004, United States

  • Center for Clinical Studies

    Webster, Texas, 77598, United States

  • Centre Hospitalier Le Mans

    Le Mans, 72037, France

  • Chang Gung Memorial Hospital

    Kaohsiung City, 83342, Taiwan

  • Chang-Gung Memorial Hospital, LinKou Branch

    Taoyuan, 333, Taiwan

  • Charite - Universitaetsmedizin Berlin (CCM)

    Berlin, 10117, Germany

  • Dawes Fretzin Clinical Research Group LLC

    Indianapolis, Indiana, 46250, United States

  • DermAssociates, PC

    Rockville, Maryland, 20850, United States

  • Derma-Study-Center Friedrichshafen GmbH

    Friedrichshafen, 88045, Germany

  • Dermatologische Gemeinschaftspraxis

    Mahlow, 15831, Germany

  • Dermatology Associates

    Seattle, Washington, 98101, United States

  • Dermatrials Research

    Hamilton, Ontario, L8N 1Y2, Canada

  • Dermed Centrum Medyczne Sp z o o

    Lodz, 90-265, Poland

  • Dermodent Centrum Medyczne Aldona Czajkowska Rafal Czajkowski S C

    Osielsko, 86031, Poland

  • Fachklinik Bad Bentheim

    Bad Bentheim, 48455, Germany

  • Forcare Clinical Research Inc

    Tampa, Florida, 33613, United States

  • Guys and St Thomas NHS Foundation Trust

    London, SE1 9RT, United Kingdom

  • HIA Sainte Anne

    Toulon, 83800, France

  • Hamzavi Dermatology

    Fort Gratiot, Michigan, 48059, United States

  • Hautarztpraxis

    Witten, 58453, Germany

  • Hopital Charles Nicolle

    Rouen, 76031, France

  • Hosp. Provincial de Pontevedra

    Pontevedra, 36001, Spain

  • Hosp. Univ. 12 de Octubre

    Madrid, 28041, Spain

  • Hosp. Univ. Germans Trias I Pujol

    Barcelona, 08916, Spain

  • Hosp. Univ. I Politecni La Fe

    Valencia, 46026, Spain

  • Hosp. de Manises

    Valencia, 46940, Spain

  • ISA - Interdisciplinary Study Association GmbH

    Berlin, 10789, Germany

  • Indiana Clinical Trial Center

    Plainfield, Indiana, 46168, United States

  • Innovaderm Research

    Montreal, Quebec, H2X 2V1, Canada

  • Klinika Ambroziak Estederm Sp. z o.o

    Warsaw, 02-953, Poland

  • Konkuk University Medical Center

    Seoul, 05030, South Korea

  • Kumamoto Kenhoku Hospital

    Tamana, 865-0005, Japan

  • Kume Clinic

    Sakai, 593 8324, Japan

  • KyungHee University Hospital

    Seoul, 102-1703, South Korea

  • Medical Dermatology Specialists

    Phoenix, Arizona, 85006, United States

  • MensingDerma research GmbH

    Hamburg, 22391, Germany

  • Mid Yorkshire Hospital NHS Trust- Pinderfields Hospital

    Wakefield, WF1 4DG, United Kingdom

  • Miyata Dermatology Clinic

    Matsudo, 271-0092, Japan

  • Modern Research Associates

    Dallas, Texas, 75231, United States

  • National Cheng Kung University Hospital

    Tainan, 70403, Taiwan

  • National Taiwan University Hospital

    Taipei, 10048, Taiwan

  • Niesmann & Othlinghaus GbR

    Bochum, 44793, Germany

  • Nomura Dermatology Clinic

    Yokohama, 221 0825, Japan

  • Nzoz Zdrowie Osteo-Medic

    Bialystok, 15-351, Poland

  • Oregon Dermatology and Research Center

    Portland, Oregon, 97210, United States

  • Pacific Skin Institute

    Sacramento, California, 95815, United States

  • Premier Clinical Research

    Spokane, Washington, 99202, United States

  • Pusan National University Hospital

    Busan, 49241, South Korea

  • Renstar Medical Research

    Ocala, Florida, 34470, United States

  • Rosenpark Research GmbH

    Darmstadt, 64283, Germany

  • Rothhaar Studien GmbH

    Berlin, 10783, Germany

  • Russell's Hall Hospital

    Dudley, DY1 2HQ, United Kingdom

  • Sapporo Skin Clinic

    Sapporo, 060 0063, Japan

  • Seoul National University Bundang Hospital

    Gyeonggi-do, 13620, South Korea

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • Shirasaki Dermatology Clinic

    Takaoka, 933-0871, Japan

  • Shizuoka General Hospital

    Shizuoka, 420-8527, Japan

  • Takagi Dermatological Clinic

    Obihiro-shi, 080-0013, Japan

  • Toyama Prefectural Central Hospital

    Toyama, 930 8550, Japan

  • Universitaetsklinikum Heidelberg

    Heidelberg, 69120, Germany

  • Universitatsklinikum Frankfurt

    Frankfurt am Main, 60590, Germany

  • Universitatsklinikum Leipzig AOR

    Leipzig, 04103, Germany

  • Universitatsklinikum Schleswig Holstein Kiel

    Kiel, 24105, Germany

  • University Hospital Southampton NHS Foundation Trust

    Southampton, SO16 6YD, United Kingdom

  • University of Pittsburgh Department of Dermatology

    Pittsburgh, Pennsylvania, 15213, United States

  • Virginia Clinical Research

    Norfolk, Virginia, 23502, United States

  • Vivida Dermatology

    Las Vegas, Nevada, 89119, United States

  • Windsor Dermatology, PC

    East Windsor, New Jersey, 08520, United States

  • Wro Medica

    Wroclaw, 51-685, Poland

  • XLR8 Medical Research

    Windsor, Ontario, N8W 1E6, Canada

  • Yamanashi Prefectural Central Hospital

    Kofu, 400-8506, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.